The Biotech Growth Trust


£328.3m market cap

734p last close

The Biotech Growth Trust seeks capital appreciation through investing in the worldwide biotechnology industry, mainly in emerging biotechnology companies. Performance is measured against its benchmark index, the NASDAQ Biotechnology Index (sterling adjusted).

Investment summary

The Biotech Growth Trust (BIOG) is managed by Geoff Hsu and Richard Klemm of OrbiMed Capital and aims to generate long-term capital growth from a diversified portfolio of global biotech equities. Investment performance has improved markedly in 2019, following a tough few years, and the managers retain their record of long-term outperformance versus the NASDAQ Biotechnology index. They remain very optimistic on the prospects for the global biotech sector, citing a favourable regulatory environment, a ‘golden era of innovation’ and an uptick in merger and acquisition activity, and believe that political noise in the run-up to the 2020 US presidential election will be manageable for the industry.

Share price graph
Price performance
Actual 7.9 (5.2) 4.9
Relative* 6.6 (7.0) 1.2
52-week high/low 806.0p/600.0p
*% relative to local index
Key management
Andrew Joy Chairman
Geoffrey Hsu Fund manager
Richard Klemm Fund manager

You may also be interested in…